Ozmosi | Oxaliplatin Drug Profile
Drug Search Results
Using advanced filters...
Advanced Search [+]

Oxaliplatin

Alternative Names: oxaliplatin, act-078, eloxatin, xa-03, xa 03, xa03, OXALIPLATINO
Clinical Status: Inactive
Latest Update: 2026-01-14
Latest Update Note: Clinical Trial Update

Product Description

Oxaliplatin is a type of chemotherapy drug. It is also called Eloxatin. It's a treatment for bowel cancer and some other types of cancer. You usually have oxaliplatin in combination with other chemotherapy drugs. It depends on the type of cancer you have as to which drugs you have it with. (Sourced from: https://www.cancerresearchuk.org/about-cancer/cancer-in-general/treatment/cancer-drugs/drugs/oxaliplatin-eloxatin)

Mechanisms of Action: DNA Synthesis Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Intravenous

FDA Designation: *

Approval Status: Approved

Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam

Approved Indications: None

Known Adverse Events: None

Company: Sanofi
Company Location: Europe
Company CEO: Paul Hudson
Additional Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Oxaliplatin

Countries in Clinic: Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Denmark, Finland, France, Germany, Greece, Hungary, India, Ireland, Israel, Italy, Japan, Korea, Mexico, Netherlands, Norway, Poland, Portugal, Puerto Rico, Slovakia, South Korea, Spain, Sweden, Switzerland, Taiwan, Turkey, United Kingdom, United States, Unknown Location

Active Clinical Trial Count: 93

Recent & Upcoming Milestones

Highest Development Phases

Phase 3: Adenocarcinoma|Biliary Tract Cancer|Colorectal Cancer|Diffuse Large B-Cell Lymphoma|Esophageal Cancer|Gastrointestinal Cancer|Lymphoma, Non-Hodgkin|Pancreatic Cancer

Phase 2: Bladder Cancer|Breast Cancer|Chemical and Drug Induced Liver Injury|Cholangiocarcinoma|Digestive System Cancer|Esophageal Diseases|Gallbladder Cancer|Hepatic Veno-Occlusive Disease|Hepatocellular Carcinoma|Intestinal Diseases|Liver Cancer|Lung Cancer|Lymphoma, B-Cell|Pancreatic Ductal Carcinoma|Peritoneal Cancer|Squamous Cell Carcinoma|Stomach Diseases

Phase 1: Epilepsy|Muscle Spasticity|Oncology Solid Tumor Unspecified

Trial ID

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Latest Trial Update Date

Data Updated

NCT06225622

CSPC-DEY-CRC-K01

P1

Recruiting

Colorectal Cancer

2026-01-01

21%

2024-11-27

Primary Endpoints|Treatments

CTR20200664

CTR20200664

P1

Completed

Oncology Solid Tumor Unspecified

2023-06-08

2025-04-29

Patient Enrollment|Primary Completion Date|Study Completion Date|Treatments|Trial Status

ACTRN12619001723178p

2006-7041-83/hah

P1

Not yet recruiting

Muscle Spasticity|Epilepsy

2020-02-24

NCT06258525

IIT2022-11-Gangi-SAMe

P2

Not yet recruiting

Colorectal Cancer|Liver Cancer|Hepatic Veno-Occlusive Disease|Chemical and Drug Induced Liver Injury

2028-04-01

2%

2025-11-05

NCT07146646

CASE2225

P2

Recruiting

Cholangiocarcinoma|Gallbladder Cancer|Biliary Tract Cancer

2027-02-01

2025-11-13

Primary Endpoints|Start Date|Treatments|Trial Status

NCT06806033

GO45434

P2

Recruiting

Lymphoma, B-Cell|Lymphoma, Non-Hodgkin

2027-01-31

12%

2025-12-24

Primary Endpoints|Start Date|Study Completion Date|Treatments

NCT05476796

LOGICAN

P2

Recruiting

Gastrointestinal Cancer|Esophageal Cancer|Adenocarcinoma

2026-01-01

41%

2023-10-18

Primary Endpoints|Start Date|Treatments

NCT06247956

SHR-8068-201-GC

P2

Active, not recruiting

Squamous Cell Carcinoma|Adenocarcinoma|Esophageal Cancer|Gastrointestinal Cancer

2025-12-30

2%

2025-09-04

Patient Enrollment|Primary Completion Date|Primary Endpoints|Treatments|Trial Status

NCT04469556

PASS-01

P2

Active, not recruiting

Adenocarcinoma|Pancreatic Ductal Carcinoma|Pancreatic Cancer

2025-01-01

2024-11-27

Primary Endpoints|Treatments

NCT05494060

EXPLORING

P2

Recruiting

Adenocarcinoma|Esophageal Diseases|Gastrointestinal Cancer|Stomach Diseases|Intestinal Diseases|Digestive System Cancer|Esophageal Cancer

2024-12-01

41%

2023-11-08

Primary Endpoints|Start Date|Treatments|Trial Status

NCT04430738

SGNTUC-024

P2

Active, not recruiting

Gastrointestinal Cancer|Adenocarcinoma|Colorectal Cancer|Cholangiocarcinoma|Esophageal Cancer|Bladder Cancer

2024-07-31

12%

2025-09-10

Primary Endpoints

2017-000927-29

CRC-PIPAC

P2

Active, not recruiting

Peritoneal Cancer|Colorectal Cancer

2020-01-31

2022-03-13

Treatments

NCT06571461

HE072-006

P3

Not yet recruiting

Pancreatic Cancer

2028-01-01

17%

2024-11-27

Primary Endpoints|Treatments

NCT06929624

SHR-A1912-301

P3

Recruiting

Diffuse Large B-Cell Lymphoma

2027-03-01

71%

2025-05-14

Primary Endpoints|Start Date|Treatments|Trial Status

NCT06624085

GO44900

P1

Recruiting

Diffuse Large B-Cell Lymphoma

2030-03-31

50%

2025-06-05

Primary Completion Date|Primary Endpoints|Treatments

2023-509814-12-00

2023-509814-12-00

P2

Recruiting

Colorectal Cancer

2031-03-31

2025-05-02

2020-003134-20

MEND-IT

P2

Active, not recruiting

Colorectal Cancer

2030-05-17

2022-03-13

Treatments

NCT07281768

J25118

P2

Not yet recruiting

Colorectal Cancer|Adenocarcinoma

2030-03-01

12%

2025-12-16

Primary Endpoints|Treatments

2024-516791-15-00

GO45434

P2

Recruiting

Diffuse Large B-Cell Lymphoma

2029-04-30

2025-05-02

Treatments

NCT07238283

HR070803-308

P3

Recruiting

Pancreatic Cancer

2028-10-01

2025-12-11

Primary Endpoints|Start Date|Treatments|Trial Status

NCT06521255

ICP-CL-00903

P3

Recruiting

Diffuse Large B-Cell Lymphoma

2028-09-01

2025-08-27

Primary Endpoints|Treatments

2020-002141-42

PelvEx II

P3

Active, not recruiting

Colorectal Cancer

2028-07-03

2022-03-13

Treatments

NCT04495088

ACO/ARO/AIO-18.2

P3

Recruiting

Colorectal Cancer

2030-08-01

2020-11-13

Primary Endpoints|Start Date

NCT06205485

NEO-RT

P3

Recruiting

Colorectal Cancer

2030-01-30

2024-08-14

Primary Endpoints|Start Date

2022-501181-22-01

STEREOPAC-001

P2

Recruiting

Adenocarcinoma|Pancreatic Cancer

2032-10-01

2025-05-02

Treatments